The Second Act of Biotech
I'm LongbridgeAI, I can summarize articles.Post-pandemic, Pfizer and Moderna are pivoting to new growth strategies. Pfizer acquired Metsera for ~$7 billion to advance berobenatide, an ultra-long-acting GLP-1 agonist for obesity, showing promising Phase 2b weight loss data. Meanwhile, Moderna is leveraging its vaccine technology to develop personalized cancer treatments. These moves reflect a broader biotech transition toward targeting specific biological systems like appetite and immunity.
Pfizer sells dopamine. Moderna made the COVID vaccine. Both are betting their next decade on medicines that barely existed when their stocks peaked.
The pandemic created one of the strangest distortions in pharmaceutical history, and left some of its biggest winners facing the same question: what comes next?
Pfizer (PFE) generated $100.3 billion of revenue in 2022. Moderna went from a biotech company with no commercial products to one of the world's most valuable vaccine businesses. Then COVID revenues collapsed, earnings followed, and investors stopped valuing what these companies had done and started asking what they could do next.
That second act is now arriving.
Pfizer has made obesity one of the central bets in its post-COVID growth strategy. Moderna is trying to turn the technology behind its COVID vaccine into something considerably more ambitious: a personalized treatment for cancer.
Together, they offer a useful window into a broader transition across biotechnology. The next generation of drugs increasingly targets specific biological systems – appetite, immunity, genetic mutations, and even the dopamine-linked reward circuitry of the brain.
Pfizer's $7 Billion Bet
Pfizer's problem is unusually visible. The COVID windfall disappeared just as major products moved toward patent expiry.
Its answer increasingly centers on obesity.
In November 2025, Pfizer completed its acquisition of Metsera for $65.60 per share, approximately $7 billion in enterprise value, with another $20.65 per share potentially payable against clinical and regulatory milestones.
The centerpiece is berobenatide, formerly MET-097i and now PF-08653944, an ultra-long-acting GLP-1 receptor agonist designed to work as both a weekly and potentially monthly injection.
Phase 2b data showed up to 12.3% placebo-adjusted weight loss at 28 weeks after patients transitioned to monthly dosing, with Pfizer saying weight loss was still continuing and no plateau was observed at week 28. Pfizer is advancing an extensive obesity program that includes 10 Phase 3 trials of berobenatide and more than 20 planned and ongoing obesity studies overall.
The attraction is straightforward. The first generation of obesity medicines proved that pharmacology could produce dramatic weight loss. The next competition is increasingly about convenience, adherence, combinations, and what else these medicines might treat.
And then there is the part of the Pfizer story that sounds invented, but isn't.